Holen Sie sich die Stockscreener-App
466.40
0.89%
4.10
Handel nachbörslich:
456.00
-10.40
-2.23%
Überblick
Nachrichten
Preisverlauf
Optionskette
Financials
Warum fällt UTHR?
Forum
Prognose
Aktiensplit
Schlusskurs vom Vortag:
$462.30
Offen:
$460.34
24-Stunden-Volumen:
406.90K
Relative Volume:
0.56
Marktkapitalisierung:
$21.04B
Einnahmen:
$3.08B
Nettoeinkommen (Verlust:
$1.24B
KGV:
18.21
EPS:
25.6108
Netto-Cashflow:
$1.07B
1W Leistung:
+3.90%
1M Leistung:
+7.56%
6M Leistung:
+55.63%
1J Leistung:
+20.74%
1-Tages-Spanne:
$460.34
$470.86
1-Wochen-Bereich:
$445.81
$470.86
52-Wochen-Spanne:
$266.98
$479.50
United Therapeutics Corp Stock (UTHR) Company Profile
Firmenname
United Therapeutics Corp
Sektor
Telefon
(301) 608-9292
Adresse
1000 SPRING ST, SILVER SPRING, MD
Vergleichen Sie UTHR mit anderen Aktien
| Aktien | Preis | Marktkapitalisierung | Umsatz | Nettogewinn | Free Cashflow | ENV |
|---|---|---|---|---|---|---|
UTHR
United Therapeutics Corp
|
466.40 | 19.91B | 3.08B | 1.24B | 1.07B | 25.61 |
|
ZTS
Zoetis Inc
|
120.82 | 53.39B | 9.40B | 2.65B | 2.24B | 5.935 |
|
TAK
Takeda Pharmaceutical Co Adr
|
14.29 | 44.99B | 29.63B | 260.53M | 5.51B | 0.0788 |
|
HLN
Haleon Plc Adr
|
9.59 | 44.08B | 14.26B | 1.98B | 2.47B | 0.4327 |
|
TEVA
Teva Pharmaceutical Industries Ltd Adr
|
25.41 | 29.30B | 16.70B | -157.13M | 1.19B | -0.1446 |
United Therapeutics Corp Stock (UTHR) Upgrades & Downgrades
| Datum | Aktion | Analytiker | Ratingänderung |
|---|---|---|---|
| 2025-10-20 | Eingeleitet | Wells Fargo | Underweight |
| 2025-09-26 | Eingeleitet | RBC Capital Mkts | Outperform |
| 2025-06-02 | Eingeleitet | Cantor Fitzgerald | Overweight |
| 2025-04-25 | Herabstufung | Wells Fargo | Overweight → Equal Weight |
| 2025-04-21 | Hochstufung | BofA Securities | Underperform → Neutral |
| 2024-07-11 | Herabstufung | Morgan Stanley | Overweight → Equal-Weight |
| 2024-02-12 | Hochstufung | Goldman | Sell → Neutral |
| 2024-02-05 | Eingeleitet | Leerink Partners | Outperform |
| 2023-12-08 | Eingeleitet | Wells Fargo | Overweight |
| 2022-12-06 | Eingeleitet | UBS | Buy |
| 2022-12-05 | Eingeleitet | Goldman | Sell |
| 2022-10-11 | Eingeleitet | Morgan Stanley | Overweight |
| 2022-09-20 | Bestätigt | BofA Securities | Underperform |
| 2022-09-19 | Fortgesetzt | Wedbush | Outperform |
| 2022-02-11 | Eingeleitet | BTIG Research | Neutral |
| 2021-07-14 | Hochstufung | Argus | Hold → Buy |
| 2021-04-26 | Fortgesetzt | Credit Suisse | Outperform |
| 2021-02-01 | Hochstufung | H.C. Wainwright | Neutral → Buy |
| 2020-09-14 | Fortgesetzt | JP Morgan | Overweight |
| 2020-06-25 | Bestätigt | H.C. Wainwright | Neutral |
| 2020-03-10 | Hochstufung | Jefferies | Hold → Buy |
| 2020-02-27 | Hochstufung | Cowen | Market Perform → Outperform |
| 2020-01-31 | Hochstufung | JP Morgan | Neutral → Overweight |
| 2019-12-03 | Eingeleitet | BofA/Merrill | Underperform |
| 2019-08-01 | Hochstufung | Jefferies | Underperform → Hold |
| 2019-08-01 | Hochstufung | Ladenburg Thalmann | Neutral → Buy |
| 2019-07-01 | Hochstufung | Credit Suisse | Neutral → Outperform |
| 2019-05-17 | Hochstufung | UBS | Sell → Neutral |
| 2019-05-09 | Hochstufung | Credit Suisse | Underperform → Neutral |
| 2018-10-12 | Hochstufung | Standpoint Research | Hold → Buy |
| 2018-08-08 | Herabstufung | Credit Suisse | Neutral → Underperform |
| 2018-04-03 | Hochstufung | Credit Suisse | Underperform → Neutral |
| 2018-02-22 | Bestätigt | Barclays | Underweight |
| 2018-01-18 | Fortgesetzt | Credit Suisse | Underperform |
| 2017-12-27 | Bestätigt | Wedbush | Outperform |
| 2017-04-27 | Bestätigt | Wedbush | Outperform |
| 2017-03-30 | Eingeleitet | UBS | Sell |
| 2017-03-16 | Eingeleitet | Credit Suisse | Underperform |
Alle ansehen
United Therapeutics Corp Aktie (UTHR) Neueste Nachrichten
Can technical indicators confirm United Therapeutics Corporation’s reversal2025 Technical Patterns & Risk Adjusted Swing Trade Ideas - newser.com
Why United Therapeutics Corporation stock is trending among retail traders2025 Key Highlights & Entry Point Confirmation Alerts - newser.com
Understanding United Therapeutics Corporation’s price movementPortfolio Risk Summary & Real-Time Sentiment Analysis - newser.com
How United Therapeutics Corporation (UTH) stock reacts to stronger dollarRecession Risk & Risk Controlled Stock Alerts - newser.com
Rothblatt (United Therapeutics) sells $4.7m in UTHR stock By Investing.com - Investing.com Canada
Heatmap analysis for United Therapeutics Corporation and competitorsJuly 2025 Price Swings & Breakout Confirmation Alerts - newser.com
United Therapeutics Executives Sell Shares Worth Over $13 Million - TradingView
Chmn Rothblatt Files To Sell 4,000 Of United Therapeutics Corp [UTHR] - TradingView
United Therapeutics (UTHR): Stock Up 44.4%, Strong Growth & Cash FlowNews and Statistics - IndexBox
Is United Therapeutics Corporation (UTH) stock a top dividend aristocrat candidateJuly 2025 Sector Moves & Daily Volume Surge Signals - newser.com
3 Reasons Investors Love United Therapeutics (UTHR) - Yahoo Finance
Will United Therapeutics Corporation stock rally after Fed decisionsJuly 2025 Catalysts & Safe Investment Capital Preservation Plans - newser.com
United Therapeutics’ AI-Driven Study: A Potential Game-Changer for Pulmonary Hypertension Diagnosis - MSN
United Therapeutics Corp’s Earnings Call Highlights Growth and Innovation - MSN
United Therapeutics Chairperson & CEO Martine A. Rothblatt Sells 8,000 Shares - TradingView
United Therapeutics CorporationCommon Stock (Nasdaq:UTHR) Stock Quote - Markets Financial Content
P/E Ratio Insights for United Therapeutics - Benzinga
Is United Therapeutics Corp Gaining or Losing Market Support? - Sahm
United Therapeutics Corporation (UTHR) Stock Forecasts - Yahoo! Finance Canada
UBS Maintains United Therapeutics (UTHR) Buy Recommendation - Nasdaq
[Form 4] UNITED THERAPEUTICS Corp Insider Trading Activity - Stock Titan
United Therapeutics (NASDAQ:UTHR) CEO Sells $1,753,200.00 in Stock - MarketBeat
United Therapeutics CFO Sells Over $9 Million in Company Stock - TradingView
Will United Therapeutics Corporation stock benefit from upcoming earnings reportsQuarterly Investment Review & Advanced Technical Signal Analysis - newser.com
Access Investment Management LLC Makes New $2.14 Million Investment in United Therapeutics Corporation $UTHR - MarketBeat
United Therapeutics (NASDAQ: UTHR) sets Nov 10 & 18 talks at UBS, Jefferies; webcasts - Stock Titan
United Therapeutics Corporation $UTHR Position Lessened by Bessemer Group Inc. - MarketBeat
Combining machine learning predictions for United Therapeutics CorporationMarket Performance Recap & Verified Technical Trade Signals - newser.com
United Therapeutics Corporation (UTHR) Stock forecasts - Yahoo Finance UK
United Therapeutics Corporation Announces First Transplant in EXPAND Clinical Trial of UKidney in Patients With End-Stage Renal Disease - The Joplin Globe
United Therapeutics (Nasdaq: UTHR) starts EXPAND with first UKidney xenotransplant - Stock Titan
Insider Selling: United Therapeutics (NASDAQ:UTHR) CEO Sells 4,000 Shares of Stock - MarketBeat
United Therapeutics Hits Day High with 9.63% Surge in Stock Price - Markets Mojo
MSN Money - MSN
United Therapeutics Corp. Hits New 52-Week High of $479.50 - Markets Mojo
United Therapeutics posts record revenue but misses Q3 earnings expectations - MSN
Focus Partners Advisor Solutions LLC Buys Shares of 1,440 United Therapeutics Corporation $UTHR - MarketBeat
United Therapeutics CEO Martine A. Rothblatt Sells 8,000 Shares - TradingView
Martine Rothblatt Sells 4,000 Shares of United Therapeutics (NASDAQ:UTHR) Stock - MarketBeat
3rd Circ. Preview: BMW, MiLB And Sandoz Top Nov. Lineup - Law360
United Therapeutics (NASDAQ:UTHR) Given New $423.00 Price Target at Wells Fargo & Company - MarketBeat
Assetmark Inc. Boosts Stock Holdings in United Therapeutics Corporation $UTHR - MarketBeat
United Therapeutics Grows Revenue, But Misses Earnings Forecast - Finimize
United Therapeutics Executives Sell Shares - TradingView
United Therapeutics Corp (UTHR) Q3 2025 Earnings Call Highlights: Record Revenue Growth and ... - Yahoo Finance
Wells Fargo Maintains United Therapeutics (UTHR) Equal-Weight Recommendation - Nasdaq
United Therapeutics (NASDAQ:UTHR) Reaches New 12-Month High After Better-Than-Expected Earnings - MarketBeat
United Therapeutics price target raised to $587 from $569 at RBC Capital - TipRanks
United Therapeutics price target raised to $447 from $435 at Morgan Stanley - TipRanks
United Therapeutics (UTHR) Earnings Transcript - AOL.com
United Therapeutics Corporation (NASDAQ:UTHR) Q3 2025 Earnings Call Transcript - Insider Monkey
Finanzdaten der United Therapeutics Corp-Aktie (UTHR)
Umsatz
Nettogewinn
Free Cashflow
ENV
United Therapeutics Corp-Aktie (UTHR) Insiderhandel
| Insiderhandel | Beziehung | Datum | Transaktion | Kosten | #Aktien | Wert ($) | #Aktien Gesamt |
|---|---|---|---|---|---|---|---|
| ROTHBLATT MARTINE A | Chairperson & CEO |
Nov 12 '25 |
Option Exercise |
120.26 |
4,000 |
481,040 |
4,130 |
| ROTHBLATT MARTINE A | Chairperson & CEO |
Nov 13 '25 |
Option Exercise |
120.26 |
4,000 |
481,040 |
4,130 |
| ROTHBLATT MARTINE A | Chairperson & CEO |
Nov 13 '25 |
Sale |
728.96 |
4,000 |
2,915,859 |
130 |
| ROTHBLATT MARTINE A | Chairperson & CEO |
Nov 12 '25 |
Sale |
460.00 |
4,000 |
1,839,996 |
130 |
0.48%
0.51%
In Yahoo öffnen
|
In Google öffnen
|
In Finviz öffnen
|
In MarketWatch öffnen
|
Öffnen Sie in EDGAR
|
Offen in Reuters
Kapitalisierung:
|
Volumen (24h):